Jae‐Seok Roe

4.5k total citations
45 papers, 2.1k citations indexed

About

Jae‐Seok Roe is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Jae‐Seok Roe has authored 45 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 11 papers in Hematology and 10 papers in Oncology. Recurrent topics in Jae‐Seok Roe's work include Protein Degradation and Inhibitors (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Histone Deacetylase Inhibitors Research (8 papers). Jae‐Seok Roe is often cited by papers focused on Protein Degradation and Inhibitors (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Histone Deacetylase Inhibitors Research (8 papers). Jae‐Seok Roe collaborates with scholars based in South Korea, United States and Japan. Jae‐Seok Roe's co-authors include Christopher R. Vakoc, Hong‐Duk Youn, Eun‐Jung Cho, Darryl Pappin, Keith Rivera, Junwei Shi, Hwa-Ryeon Kim, Hyungsoo Kim, Anja Hohmann and Chun‐Hao Huang and has published in prestigious journals such as Nucleic Acids Research, The Journal of Experimental Medicine and Genes & Development.

In The Last Decade

Jae‐Seok Roe

44 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jae‐Seok Roe South Korea 22 1.6k 479 376 275 249 45 2.1k
Nilgun Tasdemir United States 15 1.1k 0.7× 349 0.7× 429 1.1× 129 0.5× 183 0.7× 26 1.6k
Jeffrey A. Magee United States 17 1.7k 1.1× 627 1.3× 729 1.9× 440 1.6× 387 1.6× 39 2.7k
Aleksandra Franovic United States 18 1.3k 0.8× 744 1.6× 600 1.6× 91 0.3× 200 0.8× 38 2.0k
Elisabetta Rovida Italy 28 1.1k 0.7× 365 0.8× 395 1.1× 392 1.4× 419 1.7× 78 2.0k
Morvarid Mohseni United States 15 1.4k 0.8× 266 0.6× 304 0.8× 210 0.8× 255 1.0× 24 2.2k
Rachel A. Altura United States 25 1.3k 0.8× 189 0.4× 590 1.6× 122 0.4× 270 1.1× 48 1.9k
Ting-Lei Gu United States 12 1.6k 1.0× 714 1.5× 277 0.7× 513 1.9× 286 1.1× 12 2.1k
Wen-Mei Yu United States 23 1.3k 0.8× 306 0.6× 298 0.8× 379 1.4× 578 2.3× 30 1.8k
Peter Staller Germany 12 1.9k 1.2× 653 1.4× 886 2.4× 105 0.4× 410 1.6× 12 2.6k
Stephanie Z. Xie United States 14 930 0.6× 237 0.5× 224 0.6× 355 1.3× 242 1.0× 22 1.6k

Countries citing papers authored by Jae‐Seok Roe

Since Specialization
Citations

This map shows the geographic impact of Jae‐Seok Roe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jae‐Seok Roe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jae‐Seok Roe more than expected).

Fields of papers citing papers by Jae‐Seok Roe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jae‐Seok Roe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jae‐Seok Roe. The network helps show where Jae‐Seok Roe may publish in the future.

Co-authorship network of co-authors of Jae‐Seok Roe

This figure shows the co-authorship network connecting the top 25 collaborators of Jae‐Seok Roe. A scholar is included among the top collaborators of Jae‐Seok Roe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jae‐Seok Roe. Jae‐Seok Roe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roe, Jae‐Seok, et al.. (2025). Current advances and future directions in targeting histone demethylases for cancer therapy. Molecules and Cells. 48(3). 100192–100192. 4 indexed citations
2.
Nam, Young, et al.. (2024). EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401. Cell Death and Differentiation. 31(10). 1318–1332. 8 indexed citations
3.
Lee, Seungyeon, Eun‐Ji Kwon, Eun‐Jung Kim, et al.. (2023). Partial in vivo reprogramming enables injury-free intestinal regeneration via autonomous Ptgs1 induction. Science Advances. 9(47). eadi8454–eadi8454. 16 indexed citations
4.
5.
Kim, Hwa-Ryeon, Hee Seung Lee, Koji Miyabayashi, et al.. (2023). A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. Gastroenterology. 165(1). 133–148.e17. 5 indexed citations
6.
Hwang, Sung‐Min, Gi‐Bang Koo, Hyunjin Noh, et al.. (2022). LCK‐Mediated RIPK3 Activation Controls Double‐Positive Thymocyte Proliferation and Restrains Thymic Lymphoma by Regulating the PP2A‐ERK Axis. Advanced Science. 9(32). e2204522–e2204522. 9 indexed citations
7.
Lee, Jae Eun, Seon‐Kyu Kim, Jae‐Seok Roe, et al.. (2021). GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner. Cancer Letters. 521. 294–307. 30 indexed citations
8.
Lim, Jisun, Jinbeom Heo, Hyein Ju, et al.. (2020). Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway. Science Advances. 6(16). eaba1334–eaba1334. 43 indexed citations
9.
Kim, Hwa-Ryeon, Ho Yeon Lee, Junhyung Park, et al.. (2019). Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4–Induced Metabolic and Oxidative Stress. Cancer Research. 79(22). 5849–5859. 25 indexed citations
10.
Shin, Soyeon, Kyungeun Kim, Hwa-Ryeon Kim, et al.. (2019). Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer. Cell Death and Differentiation. 27(4). 1341–1354. 37 indexed citations
11.
Kim, Sung‐Eun, Yubin Kim, JungHo Kong, et al.. (2019). Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. eLife. 8. 25 indexed citations
12.
Tasdemir, Nilgun, Ana Banito, Jae‐Seok Roe, et al.. (2016). BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. Cancer Discovery. 6(6). 612–629. 278 indexed citations
13.
Roe, Jae‐Seok & Christopher R. Vakoc. (2016). The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia. Cold Spring Harbor Symposia on Quantitative Biology. 81. 61–66. 18 indexed citations
14.
Bhagwat, Anand, et al.. (2016). BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. Cell Reports. 15(3). 519–530. 120 indexed citations
15.
Shen, Chen, Jonathan J. Ipsaro, Junwei Shi, et al.. (2015). NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. Molecular Cell. 60(6). 847–859. 109 indexed citations
16.
Roe, Jae‐Seok & Christopher R. Vakoc. (2014). C/EBPα: critical at the origin of leukemic transformation. The Journal of Experimental Medicine. 211(1). 1–4. 21 indexed citations
17.
Jang, Hyonchol, et al.. (2013). Phosphorylation and ubiquitination-dependent degradation of CABIN1 releases p53 for transactivation upon genotoxic stress. Nucleic Acids Research. 41(4). 2180–2190. 17 indexed citations
18.
Hwang, In‐Young, et al.. (2012). pVHL-Mediated Transcriptional Repression of c-Myc by Recruitment of Histone Deacetylases. Molecules and Cells. 33(2). 195–202. 13 indexed citations
19.
Roe, Jae‐Seok, In‐Young Hwang, Nam‐Chul Ha, et al.. (2011). Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation. Cell Cycle. 10(22). 3920–3928. 21 indexed citations
20.
Roe, Jae‐Seok & Hong‐Duk Youn. (2006). The Positive Regulation of p53 by the Tumor Suppressor VHL. Cell Cycle. 5(18). 2054–2056. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nilgun Tasdemir Breakdown of academic impact, for papers by Jeffrey A. Magee Breakdown of academic impact, for papers by Aleksandra Franovic Breakdown of academic impact, for papers by Elisabetta Rovida Breakdown of academic impact, for papers by Morvarid Mohseni Breakdown of academic impact, for papers by Rachel A. Altura Breakdown of academic impact, for papers by Ting-Lei Gu Breakdown of academic impact, for papers by Wen-Mei Yu Breakdown of academic impact, for papers by Peter Staller Breakdown of academic impact, for papers by Stephanie Z. Xie
Rankless by CCL
2026